Mercer Global Advisors’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Mercer Global Advisors's SMMT Position: Q3 2026 in Review
Mercer Global Advisors opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 51,203 shares worth $866K. The stake represents ﹤0.01% of the portfolio and ranks #1939 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in SMMT as recently as Q2 2025.
Mercer Global Advisors first reported a position in SMMT in Q1 2021 and has held it in 19 quarters since. The position peaked at $901K in Q3 2024. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Mercer Global Advisors held 51,203 shares of Summit Therapeutics worth $866K as of Q3 2026.
- Summit Therapeutics was a new Mercer Global Advisors position in Q3 2026.
- Summit Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #1939 holding.
- Mercer Global Advisors first reported a position in Summit Therapeutics in Q1 2021 and has held it in 19 quarters since.
- Mercer Global Advisors's Summit Therapeutics position peaked at $901K in Q3 2024.
- 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.